Positron Emission Tomography in Diagnosis and Management of Invasive Breast Cancer: Current Status and Future Perspectives
References (73)
- et al.
The potential of F-18-FDG PET in breast cancer: detection of primary lesions, axillary lymph node metastases, or distant metastases
Clin Positron Imaging
(2000) - et al.
Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy?
Acad Radiol
(2002) - et al.
Skeletal metastases from breast cancer: imaging with nuclear medicine
Semin Nucl Med
(1999) - et al.
The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer
Clin Positron Imaging
(2000) - et al.
Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography
Clin Breast Cancer
(2001) - et al.
Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy
Acad Radiol
(2002) - et al.
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients
Clin Breast Cancer
(2000) - et al.
Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography
Eur J Cancer
(2002) - et al.
Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma
Lancet
(1984) - et al.
Cancer statistics, 2003
CA Cancer J Clin
(2003)
A tabulated summary of the FDG PET literature
J Nucl Med
Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective
J Nucl Med
Application of annihilation coincidence detection to transaxial reconstruction tomography
J Nucl Med
Molecular imaging of cancer with positron emission tomography
Nat Rev Cancer
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations
J Clin Oncol
Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose
Radiology
The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease
Ann Surg
[Whole body positron emission tomography in breast cancer]
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr
Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
Cancer
Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
Radiology
Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings
Ann Surg Oncol
Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
J Clin Oncol
Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability
Eur J Nucl Med
Detectability of FDG-PET and MIBI-SPECT to breast cancer [abstract]
J Nucl Med
Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours
Eur J Nucl Med
Diagnostic value of positron emission tomography for detecting breast cancer
World J Surg
Effect of patients' being prone during FDG PET for the diagnosis of breast cancer
AJR Am J Roentgenol
The usefulness of breast cancer screening using 18F FDG PET [abstract]
J Nucl Med
Comparison of FDG-PET with MIBISPECT in the detection of breast cancer and axillary lymph node metastasis
J Comput Assist Tomogr
Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures
Eur J Nucl Med
Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer
J Nucl Med
Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography
J Clin Oncol
FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers
Eur J Nucl Med Mol Imaging
Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission tomography (FDG-PET) in medial hemisphere breast cancer [abstract]
J Nucl Med
Sentinel lymph node biopsy: strategies for pathologic examination of the specimen
J Surg Oncol
Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet!
Breast Cancer Res Treat
Cited by (46)
Imaging
2019, Abeloff’s Clinical OncologyPhase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients withHER2 overexpression or amplification
2013, BreastCitation Excerpt :However, FDG-PET is superior compared to CT scan in detection of internal mammary and mediastinal lymph nodes [22]. Sensitivity, specificity and accuracy for internal mammary and mediastinal lymph nodes were 85%, 90% and 88% respectively for FDG-PET, compared to 54%, 85% and 73% respectively for CT scan [23]. FDG-PET may provide additional information in early stages of breast cancer.
Imaging
2013, Abeloff's Clinical Oncology: Fifth EditionFDG-PET Dynamic Contrast-Enhanced CT in the Management of Breast Cancer
2009, PET ClinicsCitation Excerpt :For breast cancer, FDG-PET often shows locoregional or unsuspected distant disease and is particularly helpful for evaluating chemotherapy response in patients who have locally advanced breast carcinoma and those who have metastatic disease.12 Whole body FDG-PET can provide functional information that is not provided by anatomic imaging modalities such as CT or mammography, and can help narrow the differential diagnosis of breast masses, stage the cancer, and monitor patients posttreatment.9,13 FDG-PET has an important role in predicting tumor response in patients who have locally advanced breast cancer undergoing neoadjuvant chemotherapy, and differentiating scar tissue from cancer recurrence.9,14
Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer
2008, Clinical RadiologyCitation Excerpt :The majority of FDG-PET research studies have been performed on patients with invasive breast cancer. In a meta-analysis, Wu and Gambhir33 reported that the overall sensitivity, specificity, and accuracy of FDG-PET in the detection of primary invasive breast cancer are 90, 92, and 93%, respectively. In a large study of single-phase PET for beast tumour imaging, Avril et al.,32 found that the major limitation was a poor detection rate for small (pT1a and pT1b) breast carcinomas.
<sup>18</sup>F-Labeled PET and PET/CT Compounds in Oncology
2008, Fluorine and Health